{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:33:27Z","timestamp":1789914807136,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001206.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000}}],"reference-count":270,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001206.pub3","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T14:02:05Z","timestamp":1508421725000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Pharmacotherapy for social anxiety disorder (SAnD)"],"prefix":"10.1002","volume":"2019","author":[{"given":"Taryn","family":"Williams","sequence":"first","affiliation":[{"name":"University of Cape Town; Department of Psychiatry and Mental Health; Education Centre, Valkenberg Hospital Private Bage X1, Observatory Cape Town South Africa 7925"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coenie J","family":"Hattingh","sequence":"additional","affiliation":[{"name":"University of Cape Town; Department of Psychiatry and Mental Health; Education Centre, Valkenberg Hospital Private Bage X1, Observatory Cape Town South Africa 7925"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M","family":"Kariuki","sequence":"additional","affiliation":[{"name":"University of Cape Town; Department of Psychiatry and Mental Health; Education Centre, Valkenberg Hospital Private Bage X1, Observatory Cape Town South Africa 7925"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A","family":"Tromp","sequence":"additional","affiliation":[{"name":"University of Cape Town; Faculty of Health Sciences; 4 Roughmoor Rd, Mowbray Cape Town Western Cape South Africa 7700"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton J","family":"van Balkom","sequence":"additional","affiliation":[{"name":"VU-University Medical Centre and GGZ inGeest; Department of Psychiatry and EMGO+ Institute; A.J. Ernststraat 887 Amsterdam Netherlands 1081 HL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Ipser","sequence":"additional","affiliation":[{"name":"University of Cape Town; Department of Psychiatry and Mental Health; Education Centre, Valkenberg Hospital Private Bage X1, Observatory Cape Town South Africa 7925"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J","family":"Stein","sequence":"additional","affiliation":[{"name":"University of Cape Town; Department of Psychiatry and Mental Health; Education Centre, Valkenberg Hospital Private Bage X1, Observatory Cape Town South Africa 7925"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"key":"10.1002\/14651858.CD001206.pub3-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Allgulander C Efficacy of paroxetine in social phobia - a single-center double-blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20-50 mg or placebo for 3 months 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31-Nov 4 Paris, France 1998 P.3.005","DOI":"10.1016\/S0924-977X(98)80460-4"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0447.1999.tb10845.x","article-title":"Paroxetine in social anxiety disorder: a randomised placebo-controlled study","volume":"100","author":"Allgulander","year":"1999","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.602","article-title":"Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine","volume":"19","author":"Allgulander","year":"2004","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0004|cit4","unstructured":"Mangano R Liebowitz MR Allgulander C Comparison of venlafaxine extended release and paroxetine in short-term treatment of SAD New Research Abstracts. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22 San Francisco (CA) 2003"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S1461145706006602","article-title":"Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double-blind, placebo-controlled study","volume":"10","author":"Asakura","year":"2007","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0006|cit6","unstructured":"29060\/502 Randomised, double-blind study of paroxetine and placebo in the treatment of social phobia www.gsk-clinicalstudyregister.com\/study\/29060\/502#rs"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","article-title":"Paroxetine in social phobia\/social anxiety disorder. Randomised, double-blind, placebo-controlled study","volume":"175","author":"Baldwin","year":"1999","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0008|cit8","first-page":"402","article-title":"A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa","volume":"89","author":"Stein","year":"1999","journal-title":"South African Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/026988110201600412","article-title":"Efficacy of olanzapine in social anxiety disorder: a pilot study","volume":"16","author":"Barnett","year":"2002","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archgenpsychiatry.2010.11","article-title":"A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder","volume":"67","author":"Blanco","year":"2010","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.179.1.23","article-title":"Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia","volume":"179","author":"Blomhoff","year":"2001","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0012|cit12","unstructured":"Blomhoff S Haug TT Humble M Hallstrom K Madsbu HP Wold JE Treatment of generalized social phobia New Research Abstracts. 152nd Annual Meeting of the American Psychiatric Association; May 15-20 Washington DC 1999 NR650"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1192\/bjp.182.4.312","article-title":"Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial","volume":"182","author":"Haug","year":"2003","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/ebmh.6.3.90","article-title":"The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia","volume":"6","author":"Walker","year":"2003","journal-title":"Evidence-based Mental Health"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.janxdis.2007.03.001","article-title":"Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder","volume":"22","author":"Book","year":"2008","journal-title":"Journal of Anxiety Disorders"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1530-0277.2007.00546.x","article-title":"A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?","volume":"32","author":"Thomas","year":"2008","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00004714-199810000-00004","article-title":"Discontinuation of clonazepam in the treatment of social phobia","volume":"18","author":"Connor","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199312000-00008","article-title":"Treatment of social phobia with clonazepam and placebo","volume":"13","author":"Davidson","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD001206.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/00005053-199612000-00003","article-title":"A 2-year follow-up of social phobia. Status after a brief medication trial","volume":"184","author":"Sutherland","year":"1996","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/01.jcp.0000106222.36344.96","article-title":"Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder","volume":"24","author":"Davidson","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0021|cit21","unstructured":"Davidson JR Hemby LW Barbato L Van der Hoop RG Fluvoxamine controlled release for the treatment of generalized social anxiety disorder 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10-14; San Juan, Puerto Rico 2000 161"},{"issue":"7","key":"10.1002\/14651858.CD001206.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.brat.2013.03.007","article-title":"Fear, avoidance and physiological symptoms during cognitive-behavioral therapy for social anxiety disorder","volume":"51","author":"Aderka","year":"2013","journal-title":"Behaviour Research and Therapy"},{"issue":"10","key":"10.1002\/14651858.CD001206.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archpsyc.61.10.1005","article-title":"Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia","volume":"61","author":"Davidson","year":"2004","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD001206.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1176\/appi.ajp.161.8.1485","article-title":"Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder","volume":"161","author":"Huppert","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/da.20121","article-title":"Impact of depressive symptoms on the treatment of generalized social anxiety disorder","volume":"22","author":"Ledley","year":"2005","journal-title":"Depression and Anxiety"},{"issue":"1 Pt B","key":"10.1002\/14651858.CD001206.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00002826-199202001-00122","article-title":"Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits","volume":"15","author":"Fahlen","year":"1992","journal-title":"Clinical Neuropharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1600-0447.1995.tb09596.x","article-title":"Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study","volume":"92","author":"Fahlen","year":"1995","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001206.pub3-BIB0028|cit28","first-page":"S525-6","article-title":"Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo-controlled, fixed-dose study","volume":"20","author":"Feltner","year":"2010","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"213-20","DOI":"10.1097\/YIC.0b013e32834519bd","article-title":"Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study","volume":"26","author":"Feltner","year":"2011","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biopsych.2005.03.029","article-title":"Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram or placebo","volume":"58","author":"Furmark","year":"2005","journal-title":"Biological Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD001206.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/archpsyc.55.12.1133","article-title":"Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome","volume":"55","author":"Heimberg","year":"1998","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0032|cit32","unstructured":"Kasper S Loft H Nil R Escitalopram in the treatment of social anxiety disorder XII World Congress of Psychiatry; Aug 24-9 Yokohama, Japan 2002"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0033|cit33","unstructured":"Kasper S Loft H Smith JR Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder New Research Abstracts. 155th Annual Meeting of the American Psychiatric Association; May 18-23; Philadelphia (PA) 2002"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/bjp.186.3.222","article-title":"Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study","volume":"186","author":"Kasper","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0035|cit35","first-page":"71","article-title":"Moclobemide in social phobia. A double-blind, placebo-controlled clinical study","volume":"247","author":"Katschnig","year":"1997","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"9","key":"10.1002\/14651858.CD001206.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1176\/ajp.152.9.1368","article-title":"Sertraline for social phobia: a double-blind, placebo-controlled crossover study","volume":"152","author":"Katzelnick","year":"1995","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200206000-00005","article-title":"Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study","volume":"22","author":"Kobak","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/da.20014","article-title":"Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed dose study","volume":"19","author":"Lader","year":"2004","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4088\/JCP.v65n0213","article-title":"Controlled-release paroxetine in the treatment of patients with social anxiety disorder","volume":"65","author":"Lepola","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001206.pub3-BIB0040|cit40","first-page":"252","article-title":"Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol","volume":"49","author":"Liebowitz","year":"1988","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0041|cit41","first-page":"123","article-title":"Phenelzine and atenolol in social phobia","volume":"26","author":"Liebowitz","year":"1990","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archpsyc.49.4.290","article-title":"Phenelzine vs atenolol in social phobia: a placebo-controlled comparison","volume":"49","author":"Liebowitz","year":"1992","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4088\/JCP.v63n0113","article-title":"A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder","volume":"63","author":"Liebowitz","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001206.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4088\/JCP.v64n0708","article-title":"Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study","volume":"64","author":"Liebowitz","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.v66n0213","article-title":"A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder","volume":"66","author":"Liebowitz","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archpsyc.62.2.190","article-title":"Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder","volume":"62","author":"Liebow3149018itz","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00004714-199708000-00003","article-title":"Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study","volume":"17","author":"Lott","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0048|cit48","first-page":"e228","article-title":"Effectiveness of short-term dynamic psychotherapy versus sertraline in treatment of social phobia","volume":"9","author":"Moghadam","year":"2015","journal-title":"Iranian Journal of Psychiatry and Behavioral Sciences"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/01.jcp.0000186871.04984.8d","article-title":"Mirtazapine treatment of social phobia in women. A randomized, double-blind, placebo-controlled study","volume":"25","author":"Muehlbacher","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0050|cit50","unstructured":"NCT00273039 A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder clinicaltrials.gov\/ct2\/show\/record\/NCT00273039"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0051|cit51","unstructured":"NCT00318669 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia\/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- <Phase III Study> clinicaltrials.gov\/ct2\/show\/NCT00318669"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0052|cit52","unstructured":"NCT00397722 Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) clinicaltrials.gov\/ct2\/show\/results\/NCT00397722"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0053|cit53","unstructured":"NCT00403962 A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599\/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD) clinicaltrials.gov\/ct2\/show\/NCT00403962"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0054|cit54","unstructured":"NCT00470483 A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects With Social Anxiety Disorder clinicaltrials.gov\/ct2\/show\/results\/NCT00470483"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"346-56","DOI":"10.1159\/000447013","article-title":"Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial","volume":"85","author":"Nordahl","year":"2016","journal-title":"Psychotherapy and Psychosomatics"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004714-199708000-00002","article-title":"Moclobemide in social phobia: a controlled dose response trial","volume":"17","author":"Noyes","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpp.291","article-title":"Cognitive therapy versus moclobemide in social phobia: a controlled study","volume":"8","author":"Oosterbaan","year":"2001","journal-title":"Clinical Pscyhology and Psychotherapy"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","article-title":"Treatment of social phobia with gabapentin: a placebo-controlled study","volume":"19","author":"Pande","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Feltner DE Davidson JR Pollack MH Stein MB Futterer R Jefferson JW A placebo-controlled, double-blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10-14 San Juan, Puerto Rico 2000","DOI":"10.1016\/S0924-977X(00)80439-3"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001206.pub3-BIB0060|cit60","first-page":"284","article-title":"A placebo-controlled study of pregabalin in social phobia (social anxiety disorder) [abstract]","volume":"3","author":"Feltner","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0061|cit61","unstructured":"Feltner DE Pollack MH Davidson JR Stein MB Futterer RA Jefferson JW Pregabalin treatment of social phobia New Research Abstracts. 153rd Annual Meeting of the American Psychiatric Association; May 13-18 Chicago (IL) 2000"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001206.pub3-BIB0062|cit62","first-page":"S345","article-title":"A placebo-controlled, double-blind study of pregabalin treatment of social phobia: outcome and predictors of response [abstract]","volume":"10","author":"Feltner","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.jcp.0000117423.05703.e7","article-title":"Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study","volume":"24","author":"Pande","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/da.1077","article-title":"Paroxetine for social anxiety and alcohol use in dual-diagnosed patients","volume":"14","author":"Randall","year":"2001","journal-title":"Depression & Anxiety"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Randall CL Johnson MR Thevos AK Sonne SC Willard SL Thomas SE Paroxetine improves both social anxiety and alcohol use in dual-diagnosed patients 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico 2000","DOI":"10.1002\/da.1077"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/JCP.0b013e3181bf6303","article-title":"A randomized controlled trial of atomoxetine in generalized social anxiety disorder","volume":"29","author":"Ravindran","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.jcp.0000138764.31106.60","article-title":"A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder","volume":"24","author":"Rickels","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1192\/bjp.172.1.70","article-title":"Placebo-controlled trial of moclobemide in social phobia","volume":"172","author":"Schneier","year":"1998","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"302-4","DOI":"10.1097\/YIC.0b013e32833a4d71","article-title":"Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Schutters","year":"2010","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00004714-199606000-00005","article-title":"Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation","volume":"16","author":"Stein","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD001206.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","article-title":"Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial","volume":"280","author":"Stein","year":"1998","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","article-title":"Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study","volume":"156","author":"Stein","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00004850-200207000-00002","article-title":"Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder","volume":"17","author":"Stein","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0074|cit74","unstructured":"29060\/595 A study of the maintained efficacy and safety of paroxetine versus placebo in the long-term treatment of social phobia www.gsk-clinicalstudyregister.com\/study\/29060\/595#rs"},{"issue":"12","key":"10.1002\/14651858.CD001206.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archpsyc.59.12.1111","article-title":"Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study","volume":"59","author":"Stein","year":"2002","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S146114570300364X","article-title":"Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial","volume":"6","author":"Stein","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00213-004-1957-9","article-title":"Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial","volume":"177","author":"Stein","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0078|cit78","unstructured":"Stein MB Pollack MH Mangano R Long-term treatment of generalized SAD with venlafaxine extended release 156th Annual Meeting of the American Psychiatric Association; May 17-22 San Francisco (CA) 2003 NR251"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4088\/JCP.08m04949gre","article-title":"Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial","volume":"71","author":"Stein","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.euroneuro.2009.10.005","article-title":"Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder","volume":"20","author":"Tauscher","year":"2010","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1037\/0022-006X.62.2.350","article-title":"Social phobia: a comparison of behaviour therapy and atenolol","volume":"62","author":"Turner","year":"1994","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"7","key":"10.1002\/14651858.CD001206.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.pnpbp.2007.06.027","article-title":"Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study","volume":"31","author":"Vaishnavi","year":"2007","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0083|cit83","unstructured":"Lane R Walker J Swinson R Van Ameringen M Sertraline in generalised social phobia 11th World Congress of Psychiatry; Aug 6-11 Hamburg, Germany 1999"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/ebmh.4.3.91","article-title":"Sertraline was effective and well tolerated for generalised social phobia","volume":"4","author":"Pieters","year":"2001","journal-title":"Evidence-based Mental Health"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0085|cit85","unstructured":"Van Ameringen M Oakman JM Farvolden PG Mancini C Walker JR Lane RM Predictors of sertraline response in social phobia 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10-14 San Juan, Puerto Rico 2000 163"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1176\/appi.ajp.158.2.275","article-title":"Sertraline treatment of generalised social phobia: a 20-week, double-blind, placebo-controlled study","volume":"158","author":"Ameringen","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001206.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1016\/S0924-977X(00)80418-6","article-title":"A placebo-controlled study of sertraline in generalized social phobia [abstract]","volume":"10","author":"Ameringen","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4088\/JCP.v68n0215","article-title":"Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial","volume":"68","author":"Ameringen","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0089|cit89","unstructured":"Van Ameringen MA Mancini CL Pipe B Oakman J Walker JR Kjernisted KD Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo-controlled trial 156th Annual Meeting of the American Psychiatric Association; May 17-22 San Francisco (CA) 2003 NR789"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0924-977X(92)90032-4","article-title":"Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor","volume":"2","author":"Vliet","year":"1992","journal-title":"European Neuropsychopharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD001206.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02244762","article-title":"Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine","volume":"115","author":"Vliet","year":"1994","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0092|cit92","doi-asserted-by":"crossref","unstructured":"Van Vliet I Den Boer J Westenberg H Ho Pian K Clinical effects of buspirone in social phobia, a double-blind placebo controlled study 9th European College of Neuropsychopharmacology Congress; Sept 21-25 Amsterdam, Netherlands 1996","DOI":"10.1016\/0924-977X(96)83127-0"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4088\/JCP.v58n0405","article-title":"Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study","volume":"58","author":"Vliet","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1192\/bjp.161.3.353","article-title":"Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine","volume":"161","author":"Versiani","year":"1992","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0095|cit95","first-page":"167","article-title":"Double-blind placebo controlled trial with bromazepam in social phobia","volume":"46","author":"Versiani","year":"1997","journal-title":"Jornal Brasileiro de Psiquiatria"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/00004714-200012000-00009","article-title":"Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment","volume":"20","author":"Walker","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Walker JR Van Ameringen MA Swinson RP Lane RM A 24-week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment 153rd Annual Meeting of the American Psychiatric Association; May 13-18 Chicago (IL) 2000 NR259","DOI":"10.1016\/S0924-977X(00)80419-8"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.jcp.0000104906.75206.8b","article-title":"A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder","volume":"24","author":"Westenberg","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/0269881105056526","article-title":"Levetiracetam in social phobia: a placebo controlled pilot study","volume":"19","author":"Zhang","year":"2005","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0100|cit100","unstructured":"ACTRN12608000363381 Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ACTRN12608000363381"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0101|cit101","unstructured":"ACTRN12609000091202 The use of tiagabine and gabapentin in the treatment of social anxiety disorder in 8 patients apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ACTRN12609000091202"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1185\/03007998409109561","article-title":"Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice","volume":"9","author":"Allsopp","year":"1984","journal-title":"Current Medical Research and Opinion"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0103|cit103","first-page":"294","article-title":"Ketazolam, a new long-acting benzodiazepine, in the treatment of anxious patients. A multicenter study of 2,056 patients","volume":"45","author":"Angelini","year":"1989","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"8","key":"10.1002\/14651858.CD001206.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hup.436","article-title":"Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings","volume":"2002","author":"Atmaca","year":"2002","journal-title":"Human Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4088\/JCP.v67n0319","article-title":"Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment","volume":"67","author":"Blank","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0002-9343(82)90592-7","article-title":"Effects of beta-blockade and beta-stimulation on stage fright","volume":"72","author":"Brantigan","year":"1982","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0107|cit107","first-page":"S101","article-title":"A pilot controlled trial of bupropion vs. escitalopram in generalized anxiety disorder (GAD)","volume":"30 Suppl","author":"Bystritsky","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1037\/0022-006X.71.6.1058","article-title":"Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial","volume":"71","author":"Clark","year":"2003","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0109|cit109","first-page":"1-7","article-title":"Effects of oxytocin on attention to emotional faces in healthy volunteers and highly socially anxious males","volume":"18","author":"Clark-Elford","year":"2014","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/(SICI)1520-6394(2000)11:1<27::AID-DA4>3.0.CO;2-O","article-title":"Flumazenil challenge in social phobia","volume":"11","author":"Coupland","year":"2000","journal-title":"Depression and Anxiety"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.comppsych.2008.06.009","article-title":"Treatment of social anxiety with paroxetine: mediation of changes in anxiety and depression symptoms","volume":"50","author":"Dempsey","year":"2009","journal-title":"Comprehensive Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD001206.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/npp.2014.53","article-title":"Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder","volume":"39","author":"Dodhia","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.janxdis.2008.12.004","article-title":"Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia","volume":"23","author":"Donahue","year":"2009","journal-title":"Journal of Anxiety Disorders"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/hup.846","article-title":"Tiagabine for social anxiety disorder","volume":"22","author":"Dunlop","year":"2007","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0115|cit115","unstructured":"EUCTR2004-001894-24-DE A randomised, double-blind, parallel-group, placebo-controlled fixed dose study comparing the efficacy and safety of GW597599\/paroxetine combination or paroxetine monotherapy to placebo in patients with social anxiety disorder (SAD) apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2004-001894-24-DE 2012"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00005053-198103000-00005","article-title":"The treatment of social phobia: real-life rehearsal with nonprofessional therapists","volume":"169","author":"Falloon","year":"1981","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/2167702614527948","article-title":"Attachment style moderates the effects of oxytocin on social behaviors and cognitions during social rejection: applying a research domain criteria framework to social anxiety","volume":"2","author":"Fang","year":"2014","journal-title":"Clinical Psychological Science"},{"issue":"8","key":"10.1002\/14651858.CD001206.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1017\/S1461145714000352","article-title":"Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder","volume":"17","author":"Faria","year":"2014","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0119|cit119","first-page":"S421","article-title":"A randomized, placebo controlled investigation of intranasal oxytocin in patients with anxiety","volume":"36","author":"Feifel","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/ebmh.10.2.45","article-title":"Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder","volume":"10","author":"Gale","year":"2007","journal-title":"Evidence Based Mental Health"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD001206.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/000348948509400609","article-title":"Effect of beta-blockage on singing performance","volume":"94","author":"Gates","year":"1985","journal-title":"Annals of Otology, Rhinology and Laryngology"},{"issue":"10","key":"10.1002\/14651858.CD001206.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archpsyc.1991.01810340070009","article-title":"Cognitive-behavioural and pharmacological treatments of social phobia: a controlled study","volume":"48","author":"Gelernter","year":"1991","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/npp.2014.168","article-title":"Oxytocin modulation of amygdala functional connectivity to fearful faces in generalized social anxiety disorder","volume":"40","author":"Gorka","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0124|cit124","unstructured":"Greenhill LL A multisite treatment of anxiety disorders 152nd Annual Meeting of the American Psychiatric Association; May 15-20; Washington DC 1999"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0125|cit125","first-page":"230","article-title":"Rapid anti-anxiety effects in women of picogram quantities of a 19-carbon steroid [abstract]","author":"Grosser","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.psyneuen.2009.01.005","article-title":"A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder","volume":"34","author":"Guastella","year":"2009","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1192\/bjp.142.5.512","article-title":"The effect of beta adrenergic blockade on speaker's performance and memory","volume":"142","author":"Hartley","year":"1983","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1192\/bjp.182.4.312","article-title":"Exposure therapy and sertraline in social phobia: 1-year follow up of a randomised controlled trial","volume":"182","author":"Haug","year":"2003","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001206.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-9338(13)76634-3","article-title":"Efficacy of agomelatine in more anxious elderly depressed patients. A randomized, double-blind study vs placebo","volume":"28","author":"Heun","year":"2013","journal-title":"European Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/archpsyc.63.3.298","article-title":"Augmentation of exposure therapy with D-cycloserine for social anxiety disorder","volume":"63","author":"Hofmann","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-9338(13)77043-3","article-title":"Clinical study on the efficacy and tolerability of escitalopram in patients diagnosed with social anxiety [abstract]","volume":"28","author":"Ionescu","year":"2013","journal-title":"European Psychiatry"},{"issue":"8045","key":"10.1002\/14651858.CD001206.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(77)90890-X","article-title":"Effect of oxprenolol on stage-fright in musicians","volume":"2","author":"James","year":"1977","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/014107688307600308","article-title":"Effect on pindolol on stress-related disturbances of musical performance: preliminary communication","volume":"76","author":"James","year":"1983","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD001206.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/0002-8703(84)90599-4","article-title":"Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo","volume":"108","author":"James","year":"1984","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1185\/03007997609109311","article-title":"Oxprenolol in the treatment of examination stress","volume":"4","author":"Krishman","year":"1976","journal-title":"Current Medical Research and Opinion"},{"issue":"1-3","key":"10.1002\/14651858.CD001206.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0165-0327(02)00094-0","article-title":"Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazepine administration","volume":"76","author":"Liappas","year":"2003","journal-title":"Journal of Affective Disorders"},{"issue":"7879","key":"10.1002\/14651858.CD001206.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(74)92060-1","article-title":"Beta-blocking agents in the treatment of catecholamine-induced symptoms in musicians","volume":"2","author":"Liden","year":"1974","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/(SICI)1520-6394(1999)10:3<89::AID-DA1>3.0.CO;2-5","article-title":"Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome","volume":"10","author":"Liebowitz","year":"1999","journal-title":"Depression and Anxiety"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2014.12101342","article-title":"Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder","volume":"171","author":"Liebowitz","year":"2014","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1530-0277.1992.tb00691.x","article-title":"A placebo-controlled trial of buspirone in anxious inpatient alcoholics","volume":"16","author":"Malcolm","year":"1992","journal-title":"Alcoholism Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0141|cit141","unstructured":"Mangano R Liebowitz MR Allgulander C Comparison of venlafaxine extended release and paroxetine in short-term treatment of SAD 156th Annual Meeting of the American Psychiatric Association, May 17-22 San Francisco (CA) 2003"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2006.00839.x","article-title":"Intensive group cognitive treatment and individual cognitive therapy vs treatment as usual in social phobia: a randomized controlled trial","volume":"115","author":"Mortberg","year":"2007","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1192\/bjp.131.5.486","article-title":"A clinical trial of phenelzine in anxiety depressive and phobic neuroses","volume":"131","author":"Mountjoy","year":"1977","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0144|cit144","unstructured":"NCT00118833 St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD) clinicaltrials.gov\/ct2\/show\/NCT00118833"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0145|cit145","unstructured":"NCT00248612 Psychosocial and Medication Treatment for Anxiety in Alcoholism clinicaltrials.gov\/ct2\/show\/results\/NCT00248612"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0146|cit146","unstructured":"NCT00308724 Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care clinicaltrials.gov\/ct2\/show\/NCT00308724"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0147|cit147","unstructured":"NCT00332046 fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder clinicaltrials.gov\/ct2\/show\/NCT00332046"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0148|cit148","unstructured":"NCT00343707 PET (Positron Emission Tomography)\/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients clinicaltrials.gov\/ct2\/show\/NCT00343707"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00006842-198211000-00008","article-title":"Stage fright in musicians: a model illustrating the effect of beta blockers","volume":"44","author":"Neftel","year":"1982","journal-title":"Psychosomatic Medicine"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0150|cit150","unstructured":"Oosterbaan D Van Balkom A Spinhoven Van Dyk R Cognitive behavior therapy versus moclobemide in social phobia The World Psychiatric Association's (WPA) Thematic Congress; Nov Jerusalem 1997"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0887-6185(00)00027-X","article-title":"A comparison of the efficacy of clonazepam and cognitive-behavioural group therapy for the treatment of social phobia","volume":"14","author":"Otto","year":"2000","journal-title":"Journal of Anxiety Disorders"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1192\/bjp.140.5.484","article-title":"Does tryptophan potentiate clomipramine in the treatment of agoraphobic and agoraphobic and social phobic patients","volume":"140","author":"Pecknold","year":"1982","journal-title":"British Journal of Psychiatry"},{"issue":"9 Suppl 1","key":"10.1002\/14651858.CD001206.pub3-BIB0153|cit153","first-page":"27S","article-title":"Oxytocin modulation of amygdala-frontal reactivity and connectivity to threat and at rest in social anxiety disorder [abstract]","volume":"75","author":"Phan","year":"2015","journal-title":"Biological Psychiatry"},{"issue":"17","key":"10.1002\/14651858.CD001206.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJM200104263441703","article-title":"Fluvoxamine for the treatment of anxiety disorders in children and adolescents","volume":"344","author":"Pine","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0155|cit155","unstructured":"Prasko J Moclobemide and\/or cognitive-behavior therapy in the treatment of social phobia 157th Annual Meeting of the American Psychiatric Association; May 1-6 New York (NY) 2004"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0156|cit156","first-page":"91","article-title":"Randomized, placebo-controlled effectiveness study of quetiapine XR in co-morbid depressive and anxiety disorders [abstract]","volume":"46","author":"Ravindran","year":"2014","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000468329","article-title":"Diazepam and halazepam in anxiety: some prognostic indicators","volume":"13","author":"Rickels","year":"1978","journal-title":"International Pharmacopsychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/da.20271","article-title":"Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial","volume":"25","author":"Rynn","year":"2008","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0159|cit159","unstructured":"Schuurmans J Comijs HC Emmelkamp PM Van Dyck R A randomized controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waiting list control group for anxiety disorders in older adults 32nd Congress of the British Association for Behavioural and Cognitive Psychotherapies (jointly with the European Association of Behavioural and Cognitive Therapies); Sept 7-11 Manchester, UK 2004"},{"issue":"10","key":"10.1002\/14651858.CD001206.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/appi.ajp.158.10.1725","article-title":"Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study","volume":"158","author":"Seedat","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001206.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/S0924-977X(02)80530-2","article-title":"Citalopram challenge in social anxiety disorder","volume":"12","author":"Shlik","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0162|cit162","first-page":"393","article-title":"Effect of beta-blockade during bowling competition","volume":"8","author":"Siitonen","year":"1976","journal-title":"Annals of Clinical Research"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/070674377301800109","article-title":"Controlled evaluation of intravenous drugs in the specific desensitization of phobias","volume":"18","author":"Silverstone","year":"1973","journal-title":"Canadian Psychiatric Association Journal"},{"issue":"7","key":"10.1002\/14651858.CD001206.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1017\/S1092852900000365","article-title":"Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response","volume":"15","author":"Simon","year":"2010","journal-title":"CNS Spectrums"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/070674377301800106","article-title":"Behaviour therapy versus drug therapy in the treatment of phobic neurosis","volume":"18","author":"Solyom","year":"1973","journal-title":"Canadian Psychiatric Association Journal"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0166|cit166","first-page":"239","article-title":"Phenelzine and exposure in the treatment of phobias","volume":"16","author":"Solyom","year":"1981","journal-title":"Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1089\/acm.2010.0778","article-title":"Clinical efficacy of manasamitra vataka (an Ayurveda Medication) on generalized anxiety disorder with comorbid generalized social phobia: a randomized controlled study","volume":"18","author":"Tubaki","year":"2012","journal-title":"Journal of Alternative & Complementary Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00422146","article-title":"A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety","volume":"32","author":"Tyrer","year":"1973","journal-title":"Psychopharmacologica"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0169|cit169","first-page":"S414","article-title":"MDMA buffers against cues of social rejection [abstract]","author":"Wardle","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1185\/03007995.2016.1146663","article-title":"A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan","volume":"32","author":"Asakura","year":"2016","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4088\/PCC.15m01831","article-title":"A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder","volume":"17","author":"Careri","year":"2015","journal-title":"The Primary Care Companion for CNS Disorders"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0172|cit172","first-page":"299","article-title":"Double-blind controlled study with clonazepam and placebo in social anxiety disorder","volume":"31","author":"Barquera","year":"2008","journal-title":"Salud Mental"},{"issue":"9","key":"10.1002\/14651858.CD001206.pub3-BIB0173|cit173","first-page":"236","article-title":"Reduced serotonin synthesis after pharmacological treatment of social anxiety disorder [abstract]","volume":"77","author":"Frick","year":"2015","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0174|cit174","doi-asserted-by":"crossref","unstructured":"Krylov V Pharmacological treatment of social phobia: a controlled study with alprazolam and buspirone 9th European College of Neuropsychopharmacology (ECNP) Congress Amsterdam, Netherlands 1996","DOI":"10.1016\/0924-977X(96)82970-1"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0175|cit175","unstructured":"NCT00114127 Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome clinicaltrials.gov\/ct2\/show\/NCT00114127"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0176|cit176","unstructured":"NCT00208741 Study To Evaluate The Effects Of Gabitril\u2122 In Patients With Social Anxiety Disorder clinicaltrials.gov\/ct2\/show\/NCT00208741"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0177|cit177","unstructured":"NCT00215254 Quetiapine in Social Anxiety Disorder clinicaltrials.gov\/ct2\/show\/NCT00215254"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0178|cit178","unstructured":"NCT00246441 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism clinicaltrials.gov\/ct2\/show\/NCT00246441"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0179|cit179","unstructured":"NCT00294346 Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder clinicaltrials.gov\/ct2\/show\/NCT00294346"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0180|cit180","unstructured":"NCT00485888 Flushing in Social Anxiety Disorder on Cipralex clinicaltrials.gov\/ct2\/show\/NCT00485888"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0181|cit181","unstructured":"NCT00612859 Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type) clinicaltrials.gov\/ct2\/show\/NCT00612859"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0182|cit182","unstructured":"NCT01316302 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder clinicaltrials.gov\/ct2\/show\/NCT01316302"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0183|cit183","unstructured":"NCT00182533 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders clinicaltrials.gov\/ct2\/show\/NCT00182533"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0184|cit184","unstructured":"NCT01712321 Study of Vilazodone to Treat Social Anxiety Disorder clinicaltrials.gov\/ct2\/show\/NCT01712321"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0185|cit185","unstructured":"NCT02083926 Ketamine Infusion for Social Anxiety Disorder clinicaltrials.gov\/show\/NCT02083926"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0186|cit186","unstructured":"NCT02294305 ortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder clinicaltrials.gov\/show\/NCT02294305"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0187|cit187","unstructured":"NCT02432703 A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder clinicaltrials.gov\/show\/NCT02432703"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/08039480310002110","article-title":"Phenelzine efficacy in refractory social anxiety disorder: a case series","volume":"57","author":"Aarre","year":"2003","journal-title":"Nordic Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001206.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials - a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD001206.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM199708213370810","article-title":"The promise and problems of meta-analysis","volume":"337","author":"Bailar","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/03-2","article-title":"Quantitative analysis of sponsorship bias in economic studies of antidepressants","volume":"183","author":"Baker","year":"2003","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"Journal of Psychopharmacology\ufeff"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD001206.pub3-BIB0193|cit193","first-page":"54-60","article-title":"Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety","volume":"59","author":"Ballenger","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/15622970209150621","article-title":"WFSBP Task Force on Treatment Guidelines for Anxiety O-CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders","volume":"3","author":"Bandelow","year":"2002","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"77-84","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive - compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Archives of General Psychiartry"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0006-3223(01)01294-X","article-title":"Pharmacotherapy of social anxiety disorder","volume":"51","author":"Blanco","year":"2002","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/da.10096","article-title":"Pharmalogical treatment of social anxiety disorder: a meta-analysis","volume":"18","author":"Blanco","year":"2003","journal-title":"Depression and Anxiety"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S1461145712000119","article-title":"The evidence-based pharmacotherapy of social anxiety disorder","volume":"16","author":"Blanco","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD001206.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"977-84","DOI":"10.1016\/j.biopsych.2007.03.003","article-title":"Atomoxetine improved response inhibition in adults with attention deficit\/hyperactivity disorder","volume":"62","author":"Chamberlain","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1192\/apt.3.2.66","article-title":"Pharmacotherapy for anxiety disorders: drugs available","volume":"3","author":"Cowen","year":"1997","journal-title":"Advances in Psychiatric Treatment"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14656566.2017.1285907","article-title":"A meta-analysis of pharmacotherapy for social anxiety disorder: anexamination of efficacy, moderators, and mediators","volume":"18","author":"Curtiss","year":"2017","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001206.pub3-BIB0204|cit204","first-page":"16","article-title":"Long-term treatment of social phobia with clonazepam","volume":"52","author":"Davidson","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD001206.pub3-BIB0205|cit205","first-page":"47","article-title":"Pharmacotherapy of social anxiety disorder","volume":"59","author":"Davidson","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD001206.pub3-BIB0206|cit206","first-page":"20-6","article-title":"Pharmacotherapy of social anxiety disorder: what does the evidence tell us?","volume":"67","author":"Davidson","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0207|cit207","unstructured":"Davies SJ Champion C Dawson S Sharp J Churchill R The Subway Map - a new way to visualize antidepressant classification (a Cochrane CCDAN initiative) 14th ICGP and 19th JSNP Joint Congress; 3 October Tsukuba, Japan 2014 78"},{"issue":"16","key":"10.1002\/14651858.CD001206.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1517\/14656566.2014.955472","article-title":"Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis","volume":"15","author":"Davis","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-010-2113-3","article-title":"Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials","volume":"215","author":"Menezes","year":"2011","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"39-51","DOI":"10.7326\/0003-4819-155-1-201107050-00006","article-title":"Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study","volume":"155","author":"Dechartres","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0211|cit211","first-page":"285","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2008"},{"issue":"11","key":"10.1002\/14651858.CD001206.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","article-title":"Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes","volume":"21","author":"Deeks","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0213|cit213","first-page":"285","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2008"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jama.1992.03480030052036","article-title":"Factors influencing the publication of research results: follow-up of applications submitted to two substantial review boards","volume":"267","author":"Dickersin","year":"1992","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0215|cit215","first-page":"236","article-title":"Evidence-based treatment for adult women with child abuse-related Complex PTSD: a quantitative review","volume":"14","author":"Dorrepaal","year":"2014","journal-title":"European Journal of Psychotraumatology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0216|cit216","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0217|cit217","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"issue":"8746","key":"10.1002\/14651858.CD001206.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","article-title":"Publication bias in clinical research","volume":"337","author":"Easterbrook","year":"1991","journal-title":"Lancet"},{"issue":"315(7109)","key":"10.1002\/14651858.CD001206.pub3-BIB0219|cit219","first-page":"629-34","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00004714-200106000-00011","article-title":"Psychological and pharmacological treatments of social phobia","volume":"21","author":"Fedoroff","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0222|cit222","unstructured":"Ford C Law F Guidance for the use and reduction of misuse of benzodiazepines and other hypnotics and anxiolytics in general practice www.emcdda.europa.eu\/attachements.cfm\/att_248926_EN_UK59_benzos"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archpsyc.59.5.425","article-title":"Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy","volume":"59","author":"Furmark","year":"2002","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0165-0327(87)90022-X","article-title":"Drug treatment of social phobia","volume":"13","author":"Gorman","year":"1987","journal-title":"Journal of Affective Disorders"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001206.pub3-BIB0225|cit225","first-page":"24","article-title":"Treating generalized anxiety disorder","volume":"64","author":"Gorman","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1468-2850.1997.tb00123.x","article-title":"Cognitive-behavioral and pharmacological treatments of social phobia","volume":"4","author":"Gould","year":"1997","journal-title":"Clinical Psychology - Science & Practice"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0227|cit227","first-page":"470","article-title":"Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability","volume":"25","author":"Gury","year":"1999","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0228|cit228","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"British Journal of Medical Psychology"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0231|cit231","unstructured":"Higgins JPT Greens S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org 2011"},{"issue":"35","key":"10.1002\/14651858.CD001206.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"12491-500","DOI":"10.1523\/JNEUROSCI.1860-11.2011","article-title":"Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional arousal circuit during expectation of abdominal pain","volume":"31","author":"Hubbard","year":"2011","journal-title":"Journal of Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0233|cit233","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005170.pub2","article-title":"Pharmacotherapy for anxiety disorders in children and adolescents","author":"Ipser","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0234|cit234","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007803","article-title":"Augmentation of psychotherapy with d-cycloserine for anxiety disorders","author":"Ipser","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7109","key":"10.1002\/14651858.CD001206.pub3-BIB0235|cit235","first-page":"470","article-title":"Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased","volume":"316","author":"Irwig","year":"1998","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0236|cit236","first-page":"767","article-title":"Venalafaxine in social phobia","volume":"31","author":"Kelsey","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/archpsyc.1994.03950010008002","article-title":"Lifetime and 12-month prevalence of DSM III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey","volume":"51","author":"Kessler","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200206000-00005","article-title":"Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study","volume":"22","author":"Kobak","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"74-89","DOI":"10.1016\/j.pbb.2008.01.001","article-title":"Abuse and dependence liability of benzodiazepine-type drugs: GABAA receptor modulation and beyond","volume":"90","author":"Licata","year":"2008","journal-title":"Pharmacology Biochemistry & Behavior"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000414022","article-title":"Social Phobia","volume":"22","author":"Liebowitz","year":"1987","journal-title":"Modern Problems in Pharmacopsychiatry"},{"issue":"16","key":"10.1002\/14651858.CD001206.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1176\/ajp.123.2.218","article-title":"Different ages of onset in varieties of phobias","volume":"123","author":"Marks","year":"1966","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.108.5.e83","article-title":"Atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, dose-response study","volume":"108","author":"Michelson","year":"2001","journal-title":"Pediatrics"},{"issue":"9193","key":"10.1002\/14651858.CD001206.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0246|cit246","volume-title":"Cochrane Collaboration Handbook","author":"Mulrow","year":"1997"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2007.06.027","article-title":"Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs","volume":"63","author":"Nemeroff","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0248|cit248","unstructured":"National Institute for Health and Care Excellence Common mental health problems: identification and pathways to care NICE Clinical Guideline; 2011. Available from www.nice.org.uk"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"118-32","DOI":"10.2165\/00002018-199716020-00004","article-title":"A risk-benefit assessment of buspirone in the treatment of anxiety disorders","volume":"16","author":"Pecknold","year":"1997","journal-title":"Drug Safety"},{"issue":"10","key":"10.1002\/14651858.CD001206.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0251|cit251","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jamapsychiatry.2015.15","article-title":"Reporting bias in clinical trials investigating the efficacy of second-generation antidepressants in the treatment of anxiety disorders: a report of 2 meta-analyses","volume":"72","author":"Roest","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/jama.1994.03520020084025","article-title":"Full publication of results initially presented in abstracts. A meta-analysis","volume":"272","author":"Scherer","year":"1994","journal-title":"JAMA"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001206.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"International Clinical Psychopharmacology"},{"issue":"7387","key":"10.1002\/14651858.CD001206.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0256|cit256","volume-title":"Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl","year":"2008"},{"issue":"10","key":"10.1002\/14651858.CD001206.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/appi.ajp.158.10.1725","article-title":"Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study","volume":"158","author":"Stein","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4088\/JCP.v63n0211","article-title":"Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials","volume":"63","author":"Stein","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0259|cit259","doi-asserted-by":"crossref","unstructured":"Stein DJ Hunter B Rolfe T Oakes R Paroxetine in social anxiety disorder: a remission analysis European College of Neuropsychopharmacology (ECNP) Congress; Oct Barcelona, Spain 2002","DOI":"10.1016\/S0924-977X(02)80549-1"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0260|cit260","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001206.pub2","article-title":"Pharmacotherapy for social phobia","author":"Stein","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9618","key":"10.1002\/14651858.CD001206.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(08)60488-2","article-title":"Social anxiety disorder","volume":"271","author":"Stein","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0262|cit262","doi-asserted-by":"crossref","DOI":"10.4324\/9780203124598","volume-title":"Anxiety Disorders: A Guide for Integrating Psychopharmacology and Psychotherapy (Clinical Topics in Psychology and Psychiatry). 1st edition","author":"Stahl","year":"2013"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0263|cit263","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6965","key":"10.1002\/14651858.CD001206.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/bmj.309.6965.1351","article-title":"Why sources of heterogeneity in meta-analysis should be investigated","volume":"309","author":"Thompson","year":"1994","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-0327(96)00030-4","article-title":"Busiprone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia","volume":"39","author":"Ameringen","year":"1996","journal-title":"Journal of Affective Disorders"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001206.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004850-200008002-00004","article-title":"The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials","volume":"15","author":"Linden","year":"2000","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub3-BIB0267|cit267","volume-title":"Linear Mixed Models for Longitudinal Data","author":"Verbeke","year":"2000"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"Journal of Statistical Software"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub3-BIB0269|cit269","first-page":"520","article-title":"Social phobia: epidemiology and health care","volume":"21","author":"Wancata","year":"2009","journal-title":"Psychiatrica Danubina"},{"issue":"4. Art. No.: CD","key":"10.1002\/14651858.CD001206.pub3-BIB0270|cit270","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001206.pub2","article-title":"Pharmacotherapy for social anxiety disorder","author":"Stein","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001206.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T13:53:22Z","timestamp":1664114002000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001206.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,19]]},"references-count":270,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001206.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,19]]}}}